The University of Rhode Island, Florida’s BayCare Health System, and the Memory and Aging Program at Butler Hospital are launching a clinical trial with profound implications: what if a standard eye examination inclusive of a retinal scan could detect biomarkers indicating Alzheimer’s disease decades before the life-altering symptoms develop? A powerful breakthrough in health research.
Well, this is the exact goal of a clinical trial conducted by these health providers and research centers. The clinical trial will be assessing retinal screening processes that would be used by ophthalmologists and optometrists to hopefully create a gold standard reference database of structural, anatomic and functional imaging of the retina to enable the identification and development of sensitive and reliable markers of early Alzheimer’s disease and/or risk progression.
This five-year, $5 million Atlas of Retinal Imaging in Alzheimer’s Study (ARIAS) is sponsored by BayCare Health System’s Morton Plant Hospital and St. Anthony’s Hospital and largely funded by Morton Plant Mease Health Care Foundation and St. Anthony’s Hospital Foundation in Pinellas County, Florida.
Peter Snyder, PhD, URI vice president for research and development, professor of biomedical and pharmaceutical sciences
Stuart Sinoff, MD, medical director BayCare Health System (West Region Pinellas County)
Call to Action: Interested in learning more? TrialSite News can facilitate introductions; sign up for our Daily Digest for updates.Source: The University of Rhode Island